Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Galgani

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 16, 2007
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factorsValerio Tozzi, Pietro Balestra, Rita Bellagamba, et al.
European Journal of Neurology|June 9, 2023
Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotypeAurora Zanghì, Simonetta Galgani, Paolo Bellantonio, et al.
European Journal of Neurology|March 31, 2021
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD scoreClaudio Gasperini, Luca Prosperini, Àlex Rovira, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 25, 2020
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosisLuca Prosperini, Chiara Mancinelli, Shalom Haggiag, et al.
Neurology International|August 27, 2025
Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple SclerosisElisa Petruccioli, Luca Prosperini, Serena Ruggieri, et al.
AIDS Research and Human Retroviruses|September 19, 2003
Neurocognitive performance and quality of life in patients with HIV infectionValerio Tozzi, Pietro Balestra, Simonetta Galgani, et al.
Plos One|July 31, 2019
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray)Alessandro Enrico Grimaldi, Laura De Giglio, Shalom Haggiag, et al.
Journal of Neurovirology|July 23, 2005
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohortValerio Tozzi, Pietro Balestra, Patrizia Lorenzini, et al.
Journal of Translational Medicine|April 18, 2020
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patientsMarco Chiarini, Ruggero Capra, Federico Serana, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 16, 2007
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factorsValerio Tozzi, Pietro Balestra, Rita Bellagamba, et al.
European Journal of Neurology|June 9, 2023
Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotypeAurora Zanghì, Simonetta Galgani, Paolo Bellantonio, et al.
European Journal of Neurology|March 31, 2021
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD scoreClaudio Gasperini, Luca Prosperini, Àlex Rovira, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 25, 2020
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosisLuca Prosperini, Chiara Mancinelli, Shalom Haggiag, et al.
Neurology International|August 27, 2025
Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple SclerosisElisa Petruccioli, Luca Prosperini, Serena Ruggieri, et al.
AIDS Research and Human Retroviruses|September 19, 2003
Neurocognitive performance and quality of life in patients with HIV infectionValerio Tozzi, Pietro Balestra, Simonetta Galgani, et al.
Plos One|July 31, 2019
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray)Alessandro Enrico Grimaldi, Laura De Giglio, Shalom Haggiag, et al.
Journal of Neurovirology|July 23, 2005
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohortValerio Tozzi, Pietro Balestra, Patrizia Lorenzini, et al.
Journal of Translational Medicine|April 18, 2020
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patientsMarco Chiarini, Ruggero Capra, Federico Serana, et al.
Pageof 4